MedTrace Logo

Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata

NCT03604718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-05-11

No results posted yet for this study

Summary

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Alternaria alternata in allergic patients

Conditions

  • Rhinoconjunctivitis With or Without Allergic Asthma

Interventions

BIOLOGICAL

Beltavac® Polymerized with Alternaria alternata

Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice

Sponsors & Collaborators

  • Probelte Pharma S.L.U.

    lead INDUSTRY

Principal Investigators

  • Inmaculada Buendía Jiménez · Probelte Pharma

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-07
Primary Completion
2023-01-20
Completion
2023-01-20

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604718 on ClinicalTrials.gov